These findings suggest that CTSX upregulation in the damaged dopaminergic system may be a pathogenic factor in PD, and targeting CTSX expression or activity could be a promising therapeutic strategy to protect the nigrostriatal dopaminergic pathway. This evidence concerns the gene CTSZ and Parkinson disease.